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Results A total of 35 patients received MEDI-575 QW 
(n = 23) or Q3W (n = 12). Most treatment-related adverse 
events were grade 1 or 2 in severity across all dose levels, 
with fatigue (n = 12) and nausea (n = 8) being reported 
most frequently. With no reports of dose-limiting toxicities 
(DLTs), the MTD was not reached. MEDI-575 exhibited a 
nonlinear PK profile and increased plasma platelet-derived 
growth factor-AA levels in a dose-dependent manner with 
limited immunogenicity. Stable disease was reported as the 
best tumor response in 9 of 29 evaluable patients; however, 
no objective responses were reported.
Conclusion Administration of MEDI-575 QW or Q3W 
resulted in a favorable safety profile, including a lack of 
DLTs, but without evidence of antitumor activity in patients 
with refractory solid tumors.
Keywords Receptor · Platelet · Platelet-derived growth 
factor alpha · Neoplasms · Clinical trial, phase I
Introduction
Platelet-derived growth factors (PDGFs) are peptide 
growth factors that stimulate cellular growth, proliferation, 
and differentiation, through transmembrane receptor tyros-
ine kinases PDGF receptor alpha (PDGFRα) and PDGF 
receptor beta (PDGFRβ) [1]. Inhibition of PDGFRα sign-
aling has been used as an effective therapeutic strategy in 
diseases wherein such signaling is known to be important 
for tumor progression. For example, imatinib mesylate, a 
tyrosine kinase inhibitor with activity against PDGFRα, has 
been associated with a high response rate in patients with 
chronic eosinophilic leukemia [2], in which an FIP1L1 
1-PDGFRα fusion leads to aberrant activation of PDGFRα 
in eosinophils and other hematopoietic precursors [3]. 
Abstract 
Purpose The purpose of the study was to evaluate safety 
and determine the maximum tolerated dose (MTD) of 
MEDI-575, a fully human monoclonal antibody that selec-
tively binds to platelet-derived growth factor receptor-α 
(PDGFRα), in patients with advanced solid tumors.
Methods This phase I multicenter, open-label, single-arm 
study enrolled adults in a 3 + 3 dose escalation design to 
receive MEDI-575 (3, 6, 9, 12, or 15 mg/kg) once weekly 
(QW) until toxicity or disease progression occurred. One 
0.5-mg/kg dose was given before the first dose in the 3-mg/
kg cohort to determine pharmacokinetics (PK) and pharma-
codynamics under unsaturated conditions. After comple-
tion of dose escalation in the QW cohorts, patients were 
enrolled in two additional cohorts and received MEDI-575 
25 or 35 mg/kg every 3 weeks (Q3W). Secondary measures 
included assessments of PK, immunogenicity, and antitu-
mor activity.
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Targeting PDGFRα in the stromal compartment, particu-
larly in the lung, may have therapeutic potential for inhibi-
tion of tumor growth [4, 5].
MEDI-575 is an investigational human IgG2 kappa 
monoclonal antibody (mAb) that selectively binds to 
PDGFRα with a high degree of specificity, without cross-
reacting with PDGFRβ [6]. Antibody targeting of this 
receptor is designed to allow for specific inhibition of the 
PDGFRα pathway without affecting PDGFRβ signal-
ing, which has the potential for an improved toxicity pro-
file compared with less specific small molecule inhibitors 
such as imatinib [7, 8]. We report the results of the first-in-
human clinical study of MEDI-575 in adults with advanced 
solid tumors.
The primary objective of this study was to determine 
safety, maximum tolerated dose (MTD), and/or optimal 
biologic dose of MEDI-575 in adults with advanced solid 
tumors refractory to standard therapy or for which no 
standard therapy exists. Secondary objectives were assess-
ment of the pharmacokinetic (PK) profile, immunogenicity, 
and antitumor activity of MEDI-575. Exploratory phar-
macodynamic analysis included determination of levels of 
selected circulating soluble proteins (e.g., PDGF-AA).
Methods
Study design
This phase I, multicenter, open-label, single-arm, dose 
escalation study was conducted at five sites in the USA 
between January 2009 and April 2012 (ClinicalTrials.gov 
identifier: NCT00816400). Up to 42 patients [five cohorts 
of 3, 6, 9, 12, or 15 mg/kg dosed once weekly (QW) and 
two cohorts of 25 or 35 mg/kg dosed once every 3 weeks 
(Q3W) of 3–6 patients each] were planned for the dose 
escalation phase. Twelve patients were planned for inclu-
sion in the dose expansion phase at doses determined from 
cohorts 1 through 7, with six patients treated on the QW 
dosing schedule and six patients treated on the Q3W dosing 
schedule. Upon review of the dose escalation data, patients 
in the dose expansion phase received either 9 mg/kg QW or 
25 mg/kg Q3W.
Patients
Patients were eligible for study inclusion if they were aged 
≥18 years, had a histologically confirmed advanced solid 
tumor refractory to standard therapy or for which no stand-
ard therapy exists, had a life expectancy ≥12 weeks, had 
a Karnofsky performance status ≥60, and had adequate 
hematologic, kidney, and liver function. Patients in the 
dose expansion phase were limited to those with one of the 
following advanced solid tumors: non-small cell lung can-
cer (NSCLC), glioblastoma multiforme, ovarian cancer, or 
synovial sarcoma.
Key exclusion criteria included any prior anti-PDGF 
or PDGFR mAb therapy, concurrent or recent (within 
4 weeks for chemotherapy or investigational therapy or 
within 6 weeks for biologic or immunologic therapies) 
standard or investigational cancer treatment, major surgery 
within 4 weeks of initiating MEDI-575, significant active 
infection requiring treatment, and use of systemic immu-
nosuppressive steroid therapy. Prior radiation therapy was 
allowed, provided that exposure did not exceed an area of 
25 % of marrow space, and toxicities from previous cancer 
therapies must have recovered to grade <2.
Dose escalation
The starting dose of MEDI-575 was based on non-clinical 
PK, pharmacodynamics, and toxicology studies in cyn-
omolgus monkeys [9]. Cohorts 1 through 5 received MEDI-
575 QW as a 60-min intravenous (IV) infusion dosed at 3, 
6, 9, 12, or 15 mg/kg on days 1, 8, and 15 of each 21-day 
treatment cycle until occurrence of unacceptable toxicity, 
documentation of disease progression, or other reasons for 
patient withdrawal. Cohort 1 received MEDI-575 0.5 mg/
kg 1 week before the first 3-mg/kg dose to determine PK 
and pharmacodynamics under unsaturated conditions. If 
MTD was not reached at 15 mg/kg, cohorts 6 and 7 were 
planned to evaluate MEDI-575 dosed at 25 and 35 mg/kg 
Q3W as 90-min IV infusions until the occurrence of toxic-
ity or disease progression.
For cycle 2 and beyond, it was permissible to delay a 
dose for up to 7 days based on the occurrence of clinically 
significant grade 2 events or first occurrences of grade 3 or 
4 events, but three doses were required to complete each 
cycle. Discontinuation was required if grade ≥2 toxici-
ties did not improve to grade ≤1 within 7 days of onset, 
if grade 3 or 4 toxicities occurred with no clinical benefit 
from MEDI-575, or upon second occurrence of grade 3 or 
4 toxicities.
Assessments
Safety was assessed after the first dose through 30 days 
after the last dose. MEDI-575 concentrations in serum 
were measured with a competitive electrochemilumines-
cence (ECL) assay using the Meso Scale Discovery® plat-
form. PDGF-AA protein in human plasma was quantified 
using the Milliplex™ MAP Human Cytokine/Chemokine 
Kit (Millipore Corporation, Billerica, MA) and Luminex® 
xMAP technology platform (Luminex Corp., Austin, TX). 
An ECL-based bridging immunoassay, using a Meso 
Scale Discovery® platform, was used for the qualitative 
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determination of antidrug antibodies against MEDI-575 in 
human serum. Assessment of antitumor activity included 
physical examination and radiography. Tumor measure-
ments and assessments, which were based on Response 
Evaluation Criteria in Solid Tumors guidelines version 1.0 
(RECIST), were repeated at least 4 weeks after initial doc-
umentation of a complete or partial response.
Statistical analyses
The safety population, used for the evaluation of base-
line characteristics and safety, included all patients who 
received ≥1 dose of MEDI-575. The efficacy-evaluable 
population included patients who received ≥1 dose of 
MEDI-575 and had at least one tumor assessment after dos-
ing. The MTD-evaluable population included patients who 
received at least one full cycle of MEDI-575 and either 
experienced a dose-limiting toxicity (DLT) or completed 
the safety follow-up through the DLT evaluation period 
[28 days (cohort 1) or 21 days (cohorts 2–7)] after first 
dose of MEDI-575.
Continuous and categorical variables for all reported 
outcomes were summarized by descriptive methods. Miss-
ing data were not imputed. Time to event data, including 
time to progression (TTP), progression-free survival (PFS), 
and overall survival (OS), were evaluated using Kaplan–
Meier methods.
Pharmacokinetic parameters were estimated by non-
compartmental analysis approach using WinNonlin Pro-
fessional [version 5.2; Pharsight (Certara), Sunnyvale, 
CA]. Peak (maximum) concentration (Cmax), time to peak 
concentration (Tmax), trough serum concentration (Ctrough), 
and area under the concentration–time curve over the dos-
ing interval (AUCτ) were determined after the first dose. 
Steady-state PK parameters, including peak concentration 
(Cmax,ss) and trough concentration (Ctrough,ss), were also 
estimated. The relationship between PK and pharmaco-
dynamics was evaluated using a nonlinear mixed-effects 
model approach using NONMEM software (version 7).
Results
A total of 35 patients participated in the study. In the 
dose escalation phase, 7 cohorts (5 dosed QW and 2 
dosed Q3W) received MEDI-575 QW (n = 17) or Q3W 
(n = 6), with doses ranging from 3 to 15 mg/kg QW or 
25 to 35 mg/kg Q3W (Fig. 1). The dose expansion phase 
included 12 patients at 9 mg/kg QW (n = 6) or 25 mg/
kg Q3W (n = 6). Overall, the patient population was pre-
dominantly white (89 %), with a median age of 65 years, 
baseline Karnofsky performance status of ≥80 in 92 %, 
and with NSCLC and colon cancer as the most common 
malignancies (31 and 29 %, respectively, Table 1). All 
patients had stage III (9 %) or IV (91 %) disease at study 
entry and had received a median of six prior systemic can-
cer treatments. 
The median number of treatment cycles was 2 (range 
1–36) across dose groups, and the median number of 
MEDI-575 doses received was 6 when given QW (range 
1–107) and 2 when given Q3W (range 1–8).
Safety
No DLTs were observed and the MTD was not reached 
for either the QW or Q3W schedules. Results showed that 
Cmax levels of MEDI-575 above 150 µg/mL (optimal bio-
logic concentration) were reached, starting at doses of at 
least 6 mg/kg. Based on emerging PK–pharmacodynamic 
analyses, a dose of 9 mg/kg QW and 25 mg/kg Q3W were 
expanded, and no DLTs were noted in patients receiving 
either of these doses.
Adverse events were reported in all 35 patients. The 
most frequently reported AEs were fatigue (54 %), nausea 
(34 %), vomiting (31 %), decreased appetite (26 %), dysp-
nea (26 %), abdominal pain, hypokalemia, insomnia, and 
muscle spasm (23 % each), constipation (20 %), and dehy-
dration and diarrhea (17 % each). All treatment-related AEs 
by severity are presented in Table 2.
Overall, a total of 84 treatment-related AEs were 
reported across 24 patients: 50 (60 %) grade 1 events in 13 
patients (including 1 patient at 9 mg/kg QW with periph-
eral edema); 28 (33 %) grade 2 events in 7 patients; 5 (6 %) 
grade 3 events (including 1 patient with hypokalemia at 
9 mg/kg QW, 1 patient with fatigue and 2 with hypoka-
lemia at 25 mg/kg Q3W); and 1 (1 %) grade 4 event of 
pulmonary embolism at 9 mg/kg QW. The most frequently 
reported treatment-related AEs were fatigue (reported in 7 
patients in the 3 to 12 mg/kg QW groups; 5 patients in the 
25 and 35 mg/kg Q3W groups) and nausea (reported in 4 
patients in the 3 to 15 mg/kg QW groups; 4 patients in the 
25 and 35 mg/kg Q3W groups).
Eight of 35 patients (23 %) discontinued MEDI-575 due 
to an AE; 1 patient at the 6-mg/kg dose with diarrhea, 4 
patients at the 9-mg/kg dose (5 events: central nervous sys-
tem metastasis, pericardial effusion, cerebrovascular acci-
dent, increased alkaline phosphatase, and femur fracture), 
and 3 patients at the 25-mg/kg dose [4 events: dyspnea, 
hypercalcemia (2 events in 1 patient), and NSCLC]. No 
discontinuations were considered related to MEDI-575.
A total of 23 serious AEs were reported in 13 of 35 
(37 %) patients (Table 3). One serious AE was considered 
treatment-related; the aforementioned pulmonary embo-
lism in a patient with NSCLC treated at the 9-mg/kg QW 
dose level. The event was reported 14 days after the first 
dose of MEDI-575 and caused an interruption in dosing. 
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The patient recovered with sequelae and received a total 
of eight doses before discontinuing the study due to dis-
ease progression. By the end of the study, 29 deaths had 
occurred, 3 during treatment. All deaths were attributable 
to disease progression.
Pharmacokinetics
The mean serum concentration–time profiles of MEDI-
575 are shown in Fig. 2a and estimated PK parameters 
in Table 4. Mean serum concentrations increased with 
an increase in MEDI-575 dose following both QW and 
Q3W dosing regimens. After the first QW dose, the 
increase in mean AUCτ (days 1–8) was more than dose 
proportional, reflecting nonlinearity in the PK of MEDI-
575. However, mean AUCτ (days 1–21) increased in an 
approximately dose-proportional manner after the first 
Q3W dose of 25 and 35 mg/kg, reflecting saturation of 
nonlinear elimination pathways. The Cmax after the first 
dose increased in an approximately dose-proportional 
manner over the dose range of 0.5/3 mg/kg to 35 mg/kg. 
At steady state, the PK exposure increased in an approx-
imately dose-proportional manner over the dose range 
of 3 mg/kg to 35 mg/kg. The steady-state PK exposure 
was similar between the 12 and 15-mg/kg QW cohorts, 
likely due to higher mean body weight for patients in the 
12-mg/kg cohort compared with the 15-mg/kg cohort 
(77 vs. 68 kg). The mean linear clearance and steady-
state volume of distribution were 168 mL/day and 
4.42 L, respectively. The concentration corresponding 
to half maximum capacity (KM) for nonlinear clearance 
was 8.64 μg/mL. 
Pharmacodynamics
A dose-dependent increase in plasma concentrations of 
PDGF-AA ligand was observed following IV admin-
istration of MEDI-575 QW and Q3W, consistent with 
Treatment cycle 1
Day 1 8 15 21 28
Dose cohort 1*: 3.0 mg/kg
Dose cohort 2: 6.0 mg/kg
Dose cohort 3: 9.0 mg/kg
Dose cohort 4: 12 mg/kg
Dose cohort 5: 15 mg/kg
Dose cohort 6: 25 mg/kg
Dose cohort 7: 35 mg/kg
MEDI-575
30-Day Safety Follow-up Period
MEDI-575 will be administered once every 7 days (days 1, 8, and 15; dose cohorts
1–5) or once every 21 days (day 1; dose cohorts 6 and 7) until unacceptable toxicity,
documentation of disease progression, or other reasons for patient withdrawal.
Dose escalation to the next higher dose cohort will occur if 0 of 3 or 1 of 6 patients in
the preceding dose cohort experiences a DLT through the first 21 days (dose cohorts








Fig. 1  Dose escalation study design. The dose expansion phase 
included two additional cohorts dosed at either 9 mg/kg weekly or 
25 mg/kg every 3 weeks. *Patients enrolled in dose cohort 1 received 
a single lead-in dose of MEDI-575 at 0.5 mg/kg on day 1 (7 days 
prior to receipt of the first dose of MEDI-575 3 mg/kg on day 8)
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the dose-dependent inhibition of PDGF-AA binding to 
PDGFRα and subsequent target-mediated degradation 
(Fig. 2b). Following the lead-in dose of 0.5 mg/kg, PDGF-
AA levels increased up to 2 days, followed by a decrease 
to baseline levels on day 7 due to a decline in MEDI-575 
concentrations to levels below the limit of quantifica-
tion (BLQ). At doses higher than 3 mg/kg, the increase in 
plasma PDGF-AA ligand concentrations plateaued within 
approximately 2 days and the concentrations are sustained 
throughout the dosing interval. The PK–pharmacody-
namic analysis was performed to describe the relationship 
between MEDI-575 concentrations and PDGF-AA ligand. 
The half-maximal concentration (IC50) of MEDI-575 for 
PDGF-AA accumulation was approximately 1.5 μg/mL. 
Based on the mean IC50, greater than 99 % saturation of 
PDGFRα is expected at about 150 μg/mL of MEDI-575, 
which can be achieved with MEDI-575 9 mg/kg QW and 
25 mg/kg Q3W.
Immunogenicity
Antidrug antibodies were detected in two patients in the 
25-mg/kg Q3W cohort prior to the first administration 
of MEDI-575 on day 1 and were deemed false-positive 
results. Following the administration of MEDI-575 QW, 
antidrug antibodies were detected in one patient 30 days 
post-treatment after receiving one dose of MEDI-575 at 
0.5 mg/kg followed by six doses at 3 mg/kg. No adverse 
events associated with the antibodies were observed. Low 
antidrug antibody titers (≤39–78) were observed. No obvi-
ous impact of antidrug antibodies on the PK and pharmaco-
dynamic profiles of MEDI-575 were noted.
Antitumor activity
No objective responses based on RECIST (v1.0) were doc-
umented. The best overall response of stable disease (SD) 
Table 1  Baseline demographic and clinical characteristics
QW weekly, Q3W every 3 weeks
Parameter, n QW cohorts 1–5 (n = 23) Q3W cohorts 6 and 7 (n = 12) Total (n = 35)
Median age, years (range) 66.0 (39–83) 60.0 (50–78) 65.0 (39–83)
Sex, n (%)
 Male 11 (48) 8 (67) 19 (54)
 Female 12 (52) 4 (33) 16 (46)
Race, n (%)
 White 20 (87) 11 (92) 31 (89)
 Black 2 (9) 0 2 (6)
 Asian 1 (4) 1 (8) 2 (6)
Ethnicity, n (%)
 Hispanic or Latino 3 (13) 0 3 (9)
Karnofsky performance status, n (%)
 60 0 1 (8) 1 (3)
 70 2 (9) 0 2 (6)
 80 8 (35) 4 (33) 12 (34)
 90 12 (52) 7 (58) 19 (54)
 100 1 (4) 0 1 (3)
Primary tumor type, n (%)
 Breast adenocarcinoma 1 (4) 0 1 (3)
 Colon 6 (26) 4 (33) 10 (29)
 Endometrial 1 (4) 0 1 (3)
 Non-small cell lung 6 (26) 5 (42) 11 (31)
 Ovarian 2 (9) 1 (8) 3 (9)
 Prostate 2 (9) 1 (8) 3 (9)
 Other 5 (22) 1 (8) 6 (17)
Stage at entry, n (%)
 III 3 (13) 0 3 (9)
 IV 20 (87) 12 (100) 32 (91)
Median number of prior systemic treatments (range) 7.0 (2–16) 5.0 (2–13) 6.0 (2–16)
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occurred in 9 of 29 evaluable patients (31 %), including 
6 patients in the QW cohorts (1 of 3 at 3 mg/kg; 1 of 3 
at 6 mg/kg; 2 of 7 at 9 mg/kg; and 2 of 3 at 15 mg/kg) 
and 3 patients in the Q3W cohorts (3 of 7 at 25 mg/kg). 
Overall, for the 29 evaluable patients, median TTP and PFS 
were 1.4 months (95 % CI 1.4, 1.5 months) and median 
OS was 8.4 months (95 % CI 3.6, 10.5 months). Median 
TTP and PFS were identical between the combined QW 
and Q3W cohorts, in whom the median OS was 7.4 months 
(95 % CI 3.6, 19.4 months) and 8.6 months (95 % CI 2.4, 
10.5 months), respectively.
Discussion
In this phase I study of MEDI-575 in patients with previously 
treated advanced solid tumors, dosing up to 15 mg/kg QW and 
35 mg/kg Q3W resulted in treatment-related AEs that were 
predominantly grade 1 or 2 in severity. The MTD was not 
reached. Clinical PK and pharmacodynamic analyses iden-
tified more than 99 % PDGFRα saturation at 150 μg/mL of 
MEDI-575, and there was minimal evidence of immunogenic-
ity per detectable ADAs. Stable disease was the best tumor 
response, with no patients achieving an objective response.
Table 2  All treatment-related adverse events by dose level
QW weekly; Q3W every 3 weeks
* 1 grade 3 event
†
 2 grade 3 events
‡
 1 grade 4 event



















Anemia – – 1 1 – 2 2 – 2
Asthenia – – – – – – 1 – 1
Blood creatinine increased – – – – – – – 1 1
Chills 1 – 1 – – 2 – – –
Decreased appetite 1 – – – – 2 1 1 2
Dehydration – – – – – – 1 1 2
Diarrhea – – 1 – – 1 – 1 1
Dry mouth – – – – – – 1 – 1
Dry skin – – – – – – – 1 1
Dyspnea – – 1 – – 1 – – –
Ear discomfort – – – 1 – 1 – – –
Fatigue 2 1 3 1 – 7 3* 2 5*
Feeling abnormal – – – 1 – 1 – – –
Flushing – – – – – – – 1 1
Herpes zoster – – – – – – 1 – 1
Hypokalemia – – 3* – – 3* 2† – 2†
Hypomagnesemia – – 1 – – 1 1 1 2
Hypotension – – – – – – 1 – 1
Infusion reaction 1 – – – – 1 – – –
Insomnia – – – 1 – 1 – – –
Muscle spasms – – 1 2 – 3 1 – 1
Myalgia 1 1 – – – 2 – – –
Nausea 2 – 1 1 – 4 3 1 4
Peripheral edema – – 1 – – 1 – – –
Pulmonary embolism – – 1‡ – – 1‡ – – –
Thrombocytopenia – – – – – – 1 – 1
Urine urobilinogen increased – – – – – – 1 – 1
Vomiting 1 – 1 – – 2 1 – 1
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MEDI-575 is a human mAb that selectively binds to 
PDGFRα with high affinity, inhibiting signaling from 
PDGFRα on cancer cells and supportive stroma without 
inhibiting PDGFRβ [6]. This mechanism has important 
implications from a safety and tolerability standpoint, as 
it is recognized that inhibitors targeting both PDGFRα 
and PDGFRβ can lead to extravascular fluid accumula-
tion, likely a consequence of inhibiting PDGFRβ [7]. With 
MEDI-575, there was only one report of treatment-related 
grade 1 peripheral edema at the 9-mg/kg dose level. Most 
treatment-related AEs did not exceed grade 2, the excep-
tions being 3 reports of grade 3 hypokalemia as well as 
individual reports of grade 3 fatigue and grade 4 pulmo-
nary thromboembolism. The overall favorable safety profile 
across all MEDI-575 doses is noteworthy, especially con-
sidering the number of prior treatment regimens patients in 
this study population received.
Additional data to support the safety and tolerability of 
targeting PDGFRα in advanced malignancies are available 
from a phase 1 study of an anti-PDGFRα IgG1 mAb, olara-
tumab (formerly IMC-3G3) [10]. In that study, patients 
received 1 of 3 doses of antibody (4, 8, or 16 mg/kg) QW 
or 15 or 20 mg/kg once every 2 weeks. No DLTs or grade 
≥3 AEs were observed; however, as in our study, no objec-
tive tumor responses were reported [11]. To date, for both 
MEDI-575 and olaratumab, preclinical observations sup-
porting antitumor activity against lung tumors [6, 12] have 
not translated into advances in the clinic.
Overall, MEDI-575 exhibited nonlinear PK over the 
dose range of 0.5–35 mg/kg, which is consistent with 
receptor-mediated clearance with saturation of PDGFRα at 
doses of 3 mg/kg or higher. The systemic linear clearance 
(≈170 mL/day) and small steady-state volume of distribu-
tion (≈4 L) are in line with other mAbs [13–15]. MEDI-
575 binding with PDGFRα resulted in a dose-dependent 
increase in PDGF-AA ligand with plateau levels within 
2 days at doses ≥3 mg/kg and the concentrations are sus-
tained throughout the dosing interval. Complete target 
saturation is expected at about 150 μg/mL of MEDI-575. 
A low incidence of immunogenicity was observed, with no 
resultant impact on MEDI-575 PK and pharmacodynamic 
parameters.
The results of this study should be considered in the 
context of several limitations inherent to most open-label 
Table 3  All serious adverse events by dose level
CNS central nervous system, NSCLC non-small cell lung cancer, QW weekly, Q3W every 3 weeks
Event, n MEDI-575 dose QW MEDI-575 dose Q3W
3 mg/kg  
QW (n = 3)
6 mg/kg  
QW (n = 3)
9 mg/kg QW 
(n = 11)
12 mg/kg 
QW (n = 3)
15 mg/kg 




Q3W (n = 9)
35 mg/kg 
Q3W (n = 3)
Total Q3W 
(n = 12)
Total number of events – 1 15 – – 16 2 5 7
Total patients reporting 
≥1 event
– 1 8 – – 9 2 2 4
Pericardial effusion – – 1 – – 1 – – –
Abdominal pain – – 1 – – 1 – – –
Gastritis – – – – – – – 1 1
Pancreatitis – 1 – – – 1 – – –
Multi-organ failure – – – – – – – 1 1
Non-cardiac chest pain – – 1 – – 1 – – –
Cellulitis – – – – – – – 1 1
Femoral neck fracture – – 1 – – 1 – – –
Hyperglycemia – – 1 – – 1 – – –
Fistula – – – – – – – 1 1
CNS metastases – – 1 – – 1 – – –
NSCLC – – 3 – – 3 1 – 1
Cerebrovascular acci-
dent
– – 1 – – 1 – – –
Convulsion – – – – – – – 1 1
Confusional state – – 1 – – 1 – – –
Dyspnea – – – – – – 1 – 1
Pleural effusion – – 1 – – 1 – – –
Pneumothorax – – 2 – – 2 – – –
Pulmonary embolism – – 1 – – 1 – – –
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(non-blinded) phase I studies, which are typically con-
ducted in a small number of patients who have received 
multiple previous treatments and have refractory advanced 
disease. Most of the cohorts in this study were limited to 
three patients each.
In conclusion, MEDI-575 produced a favorable safety 
profile (including no DLTs) when administered QW or 
Q3W, but with no evidence of antitumor activity among 
adults with unselected refractory solid tumors who under-
went a median of six prior systemic cancer treatments. The 
Fig. 2  Pharmacokinetic and 
pharmacodynamic effects of 
MEDI-575. Mean a MEDI-
575 serum concentration–time 
profiles and b PDGF-AA 
plasma concentration–time 
profiles following weekly and 
every 3 week dosing regimens 
of MEDI-575. PDGF platelet-
derived growth factor, QW once 
weekly; Q3W every 3 weeks


















































Table 4  Mean pharmacokinetic parameters of MEDI-575
Values are presented as mean (standard deviation)
AUCτ area under the concentration–time curve, BLQ below the limit of quantification, Cmax peak concentration, Cmax,ss peak concentration at 
steady state, Ctrough trough serum concentration, Ctrough,ss trough concentration at steady state, ND not determined, QW weekly, Q3W every 
3 weeks, Tmax time to peak concentration
Dose (mg/kg) Tmax (day) Cmax (μg/mL) Ctrough (μg/mL) AUCτ (μg day/mL) Cmax,ss (μg/mL) Ctrough,ss (μg/mL)
0.5 0.103 (48.3) 10.9 (4.7) BLQ (ND) 25.3 (30.4) ND (ND) ND (ND)
3 QW 0.076 (71.8) 72.6 (9.6) 8.97 (31.7) 201 (6.2) 104 (20.4) 35.5 (44.5)
6 QW 0.048 (6.6) 154 (29.2) 41.5 (33.2) 524 (31.7) 287 (4.9) 144 (25.6)
9 QW 0.104 (71.0) 239 (29.0) 63.1 (39.3) 874 (46.7) 387 (39.1) 202 (97.1)
12 QW 0.130 (109.3) 590 (21.1) 144 (12.5) 1,870 (14.8) 970 (36.0) 415 (46.5)
15 QW 0.107 (35.8) 632 (3.2) 199 (27.8) 2,080 (9.8) 856 (3.3) 266 (ND)
25 Q3W 0.154 (75.5) 590 (24.4) 74.6 (48.8) 4,200 (20.9) 602 (35.8) 117 (47.8)
35 Q3W 0.064 (2.2) 918 (12.1) 223 (11.3) 8,340 (4.5) 1,160 (11.8) 159 (ND)
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next step would be to identify tumors that selectively acti-
vate the pathway to determine whether blocking the signal-
ing of the pathway with MEDI-575 may have a therapeutic 
effect.
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